MOLECULAR BIOLOGY, published by PLEIADES PUBLISHING INC, serves as a vital repository for the dissemination of innovative research within the fields of biochemistry, genetics, and molecular biology. With an ISSN of 0026-8933 and an E-ISSN of 1608-3245, this journal has been a mainstay in the scientific community since its inception, embracing its deep historical roots from 1971 to the present. Recognized for its qualitative contributions, MOLECULAR BIOLOGY is ranked in the Q3 quartile for Biophysics and Q4 for Structural Biology, placing it among select journals in its domain. Researchers and students alike benefit from its rigorous peer-reviewed articles, which focus on all aspects of molecular mechanisms and interactions. The journal's inclusion in prestigious databases underlines its commitment to academic excellence. The editorial board is dedicated to fostering the sharing of influential findings, making it an essential resource for advancing knowledge and innovation in molecular biology.

NAR Cancer, published by Oxford University Press, is a pioneering open access journal established to advance the rapidly evolving field of cancer research. Since its inception in 2019, this journal has gained substantial recognition, achieving a prestigious Q1 ranking in both Cancer Research and Oncology categories as of 2023. With a focused objective to disseminate high-quality research, reviews, and insights into innovative cancer treatments and diagnostics, NAR Cancer serves as an essential platform for researchers, healthcare professionals, and students alike. The journal is accessible for all since it became open access in 2020, ensuring a global reach and impact. Positioned in the competitive landscape of oncology, with impressive Scopus rankings, it offers a unique opportunity for contributors to share their work with an engaged and interdisciplinary audience. With a commitment to excellence, NAR Cancer is dedicated to driving forward the understanding and management of cancer worldwide.

Epigenetics, published by Taylor & Francis Inc, is a leading journal in the fields of Cancer Research, Medicine (miscellaneous), and Molecular Biology. With an ISSN of 1559-2294 and an E-ISSN of 1559-2308, this journal has been paving the way for groundbreaking research since its inception in 2006, and it continues to play a crucial role in advancing our understanding of epigenetic mechanisms and their implications in health and disease. The journal is highly regarded, ranking in the Q1 category for Medicine and Q2 for both Cancer Research and Molecular Biology according to the 2023 category quartiles. Researchers and professionals in the field will find invaluable insights and innovative studies within its pages, making it an essential resource for those engaged in cutting-edge research. Although the journal is not open access, it encourages a comprehensive understanding through high-quality peer-reviewed content. With its creative exploration of the epigenetic landscape, Epigenetics serves as a vital platform for the sharing of knowledge that could lead to breakthroughs in treatments and therapies.

Nucleus is a distinguished academic journal published by Taylor & Francis Inc, dedicated to advancing the fields of Cell Biology and Medicine. Since its inception, the journal has gained significant recognition, achieving a Q1 ranking in both Cell Biology and Medicine (miscellaneous) categories in 2023. With a focus on innovative research that intersects molecular biology and genetics, Nucleus serves as a vital platform for researchers and professionals aiming to disseminate findings that contribute to our understanding of cellular mechanisms and their implications in health and disease. The journal's commitment to Open Access since 2018 ensures that cutting-edge research is readily available to the global community, fostering collaboration and engagement across disciplines. Located in Philadelphia, PA, Nucleus not only aims to publish high-quality articles but also aspires to influence future research directions in the biological sciences, making it an essential resource for anyone involved in the life sciences.

SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY is a premier journal published by Academic Press Ltd - Elsevier Science Ltd, focusing on the vital domains of cell and developmental biology. With an impact factor that reflects its rigorous contributions to the field, this journal embodies the highest standards of academic excellence, currently ranking in the Q1 quartile for both Cell Biology and Developmental Biology categories as of 2023. Researchers and practitioners will appreciate its robust Scopus ranking, placing it within the top tiers of developmental biology and cell biology, with percentile ranks of 94th and 90th respectively, showcasing the journal's influential presence in the scientific community. The journal aims to disseminate comprehensive reviews, cutting-edge research articles, and significant advances in the understanding of cellular mechanisms and developmental processes, thereby catering to a diverse audience that includes researchers, scholars, and students dedicated to the life sciences. Given its commitment to open access, SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY promotes widespread dissemination of knowledge, enhancing collaborative research efforts and driving innovation across biological disciplines.

Non-coding RNA Research, published by KEAI PUBLISHING LTD, is a leading open-access journal dedicated to advancing the field of non-coding RNA, a critical component in the landscape of molecular biology and genetics. Established in 2016, this journal aims to provide a platform for the dissemination of high-quality research focusing on the roles, mechanisms, and therapeutic potentials of non-coding RNAs in various biological processes and diseases. With impressive Scopus rankings placing it in the top quartile for both Biochemistry and Medical Biochemistry, as well as notable standings in Genetics and Molecular Biology, Non-coding RNA Research continues to attract contributions from globally recognized experts. The journal's commitment to open access ensures broad visibility and engagement with cutting-edge discoveries, thereby fostering an inclusive scientific dialogue that enhances understanding and innovation in this rapidly evolving field. For researchers and scholars, the opportunity to publish in a Q1 ranked journal not only validates their work but also enhances its impact, making Non-coding RNA Research an indispensable resource for anyone interested in the intricate workings of non-coding RNA.

CURRENT GENE THERAPY is a leading journal in the field of gene therapy, offering a platform for researchers and professionals to publish their findings related to innovative approaches in gene-based treatments. Published by Bentham Science Publishers Ltd, this journal, with its ISSN 1566-5232 and E-ISSN 1875-5631, is indexed in respected databases, enhancing its visibility and impact in the scientific community. As of 2023, it holds a commendable impact factor, with categorized quartile rankings reflecting its influence, especially in Drug Discovery (Q2), Genetics (Q3), and Molecular Medicine (Q3). Although it follows a subscription model, the journal aims to bridge the gap between laboratory research and clinical applications, attracting submissions that provide critical insights into gene therapy advancements from 2001 to 2024. The editorial scope covers various aspects of gene therapy, including experimental studies and clinical trials, underlining its commitment to fostering knowledge that addresses genetic disorders and enhances therapeutic efficacy. Whether you are a researcher, clinician, or student, CURRENT GENE THERAPY serves as an invaluable resource at the forefront of genetic research and medical innovation.

Cancer Cell International, published by BMC, is a transformative open-access journal established in 2001, dedicated to advancing the field of oncology and cancer research. With its ISSN number not specified and an E-ISSN of 1475-2867, the journal proudly operates from the United Kingdom, located at CAMPUS, 4 Crinan St, London N1 9XW, England. Renowned for its rigorous peer-review process, Cancer Cell International has made significant strides, securing a Q2 ranking in Cancer Research and Q1 rankings in both Genetics and Oncology as of 2023. It ranks impressively in Scopus, featuring in the top quintile of Genetics (#37/347) and Oncology (#52/404), indicating its importance within the scientific community. The journal's broad scope caters to a diverse array of topics within cancer biology, making it an invaluable resource for researchers, professionals, and students seeking to stay at the forefront of cancer science. With a commitment to disseminating high-quality research, Cancer Cell International invites scholars to explore innovative findings and contribute to the collective effort of combating cancer.

NUCLEIC ACIDS RESEARCH, published by Oxford University Press, is a premier peer-reviewed journal in the field of genetics, holding a prestigious Q1 ranking in this domain as of 2023. Since its inception in 1974 and with a converged publication horizon extending to 2024, this journal has established itself as a vital resource for researchers and professionals interested in the molecular aspects of nucleic acids, encompassing DNA and RNA studies as well as their implications in biochemistry and molecular biology. With an impressive Scopus rank of #6 out of 347 in Genetics, this journal is positioned in the 98th percentile among its peers, highlighting its significant impact and relevance in the scientific community. As an open access journal since 2005, NUCLEIC ACIDS RESEARCH ensures wide dissemination of knowledge, promoting collaborative advancements in genetic research. For those looking to stay at the forefront of nucleic acid research, this journal remains an essential publication for accessing cutting-edge findings and innovative methodologies in the field.

CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, published by BEGELL HOUSE INC, serves as a vital resource within the fields of Genetics and Molecular Biology. With the ISSN 1045-4403 and E-ISSN 2162-6502, this journal has been contributing to scientific discourse since 1990 and is projected to continue its publication until 2024. Despite its classification in the Q3 quartile for both Genetics and Molecular Biology, its impact on the research community is significant, as evidenced by its diverse range of critical reviews that synthesize and analyze emerging trends and foundational studies in gene expression. The journal, located in the United States at 50 North St, Danbury, CT 06810, offers a platform for researchers, professionals, and students to engage with innovative ideas and methodologies that drive forward the understanding of gene regulatory mechanisms in eukaryotes. Although it currently does not offer open access, the journal's content remains crucial for those dedicated to advancing knowledge in the intricacies of genetic expression.